| Detected | Trial | Change |
|---|---|---|
| 2026-06-11 | NCT07517263 An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate… |
Trial sites expanded: 559 -> 618 locations |
| 2026-05-19 | NCT07517263 An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate… |
Trial sites expanded: 492 -> 559 locations |
| 2026-05-14 | NCT06813911 Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants… |
Trial sites expanded: 92 -> 96 locations |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-04 | NCT07625306 Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and… | Phase 3 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT06813911 | Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants… | Atherosclerotic Cardiovascular Disease (ASCVD) | Recruiting |
| NCT07517263 | An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate… | Cardiovascular Disease and Lipoprotein(a) | Recruiting |
| NCT06875973 | Pelacarsen Roll-over Extension Program | Atherosclerotic Cardiovascular Disease | Recruiting |
| NCT04023552 | Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major… | Cardiovascular Disease and Lipoprotein(a) | Active, Not Recruiting |
| NCT07625306 | Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and… | Acute Coronary Syndrome (ACS) | Not Yet Recruiting |
| Phase 2 | |||
| NCT05646381 | A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen… | Aortic Stenosis | Recruiting |